Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAL-MPE1 SCIT in peanut allergy
NCT02991885Phase 1Completed
- Sponsor
- HAL Allergy Group
- Start
- Dec 2016
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in peanut allergy comparing HAL-MPE1 with Placebo (2 arms). Primary endpoints: Occurrence of local and systemic reactions and Occurrence of treatment emergent adverse events at 16 weeks. Started Dec 2016; status: completed.
02
Drugs
HAL-MPE1
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02991885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991885.